| Document |
Document Title |
|
WO/2024/036226A1 |
Provided herein is a method for treating autism or autism spectrum disorders. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating autis...
|
|
WO/2024/033928A1 |
Method of increasing collagen production and tissue regeneration or repair using an agent that increases an amount of Hypoxia- inducible factor- 1 (HIF-1) in the cells, the amount being selected to cause an increase in the amount of coll...
|
|
WO/2024/031297A1 |
Provided are a recombinant adenovirus or adenoviral vector expressing GLP1 receptor agonist that shows expected anti-tumor effects and prolonged survival time in tumor-bearing subjects and the pharmaceutical composition comprising the same.
|
|
WO/2024/036044A1 |
Provided herein are compositions and methods for treating or preventing metabolic disorders and cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of phosphorylation of AMPKalpha1 at Serine496 and AM...
|
|
WO/2024/015605A9 |
The present disclosure relates to systems and methods for immune therapy. For example, a method can be used to enhance the proliferation of chimeric antigen receptor (CAR) T cells in a subject, The method comprises administering to the s...
|
|
WO/2024/031965A1 |
Disclosed are a PROTAC compound with cyclophilin A degradation activity, a preparation method therefor, and use thereof. The structural formula of the PROTAC compound is represented by formula (I). The compound represented by formula (I)...
|
|
WO/2024/032651A1 |
The present invention relates to the field of pharmaceutical synthesis. A long-acting insulin compound is disclosed. The long-acting insulin compound of the present invention for preparing a pharmaceutical composition for treating diseas...
|
|
WO/2024/036324A1 |
Provided herein are compositions and methods related to compositions comprising an Ig protease fusion protein. Also provided herein are compositions and methods for therapeutic treatment, such as of autoimmune diseases, allergies, or oth...
|
|
WO/2024/030886A1 |
The present disclosure provides, inter alia, methods for treating hemophilia A as well as computer-based-systems, including software-based pharmacokinetic model systems, and their use to determine dosing information for subjects who have...
|
|
WO/2024/029755A1 |
The present invention relates to an animal model of Charcot-Marie-Tooth disease caused by K141N or K141T mutations in HSPB8. In this animal model expressing the K141N or K141T mutant HSPB8 protein, symptoms of Charcot-Marie-Tooth disease...
|
|
WO/2024/031012A2 |
In some aspects, the present disclosure provides an implant. In some embodiments, the implant comprises a porous body comprising a form that fills a defect of a bone of a head of a subject. In some embodiments, the implant comprises a re...
|
|
WO/2024/030934A2 |
Provided herein are GLP-1 receptor antagonists peptides and pharmaceutical compositions for the treatment of hypoglycemia. Further provided herein are methods of treating atypical hypoglycemia in patients that have become hyperinsulinemi...
|
|
WO/2024/031022A2 |
Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal ...
|
|
WO/2024/027771A1 |
Provided in the present invention is an antibody fusion protein, which can specifically bind to an FAP protein and block a TGFβ signaling pathway. Further provided in the present invention are a nucleic acid molecule encoding the antibo...
|
|
WO/2024/028587A1 |
There is provided inter alia an isolated anti-cancer T-cell receptor (TCR), or anti- cancer binding fragment thereof, that binds to a plurality of cancer polypeptide antigens or antigenic peptide fragments thereof wherein said cancer pol...
|
|
WO/2024/030951A2 |
Methods for prevention of peripheral neuropathies, including taxane-induced peripheral neuropathies, by administration of MANF or nucleic acids encoding MANF are provided. Methods of treating extant peripheral neuropathies and neuropathy...
|
|
WO/2024/029992A1 |
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, which is known to be a causative agent of Alzheimer's disease, and a composition for the treatment and prevention of Alzheimer's diseas...
|
|
WO/2024/031084A2 |
Embodiments of the disclosure include methods and compositions related to use of compound comprising a particular peptide linked to a dye. In specific embodiments, the peptide DIRG is linked to the BODIPY dye. In specific embodiments, th...
|
|
WO/2024/031053A1 |
Provided herein are TDP-43 variants in which a prion-like domain (PLD) of the TDP-43 variant is mutated to have more aromatic amino acids and/or aromatic amino acids that are more evenly spaced than in a PLD from a wild type TDP-43, nucl...
|
|
WO/2024/029598A1 |
The present invention provides: a novel method which makes it possible to improve or maintain a muscle amount or muscle strength; and a novel method which makes it possible to prevent obesity, reduce a body fat percentage, reduce a body ...
|
|
WO/2024/029876A1 |
The present disclosure relates to a modified fusion proteins in which a vascular endothelial growth factor is associated with a placental growth factor, and a use thereof. The modified fusion protein according to an embodiment of the pre...
|
|
WO/2024/029242A1 |
Disclosed is a linear peptide or cyclic peptide having an amino acid sequence represented by formula (1): XN-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15 (1), or a pharmacologically acceptable salt thereof. Binding this peptide to LRP1 makes i...
|
|
WO/2024/028881A1 |
Nucleic acid molecules comprising a sequence encoding a chimeric polypeptide comprising a cytokine region comprising at least one single-chain anti-inflammatory cytokine, a transmembrane region and a at least one signaling region compris...
|
|
WO/2024/028483A1 |
The present invention relates to brain derived nerve factor (BDNF) for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said BDNF is administered intranasally to said subject.
|
|
WO/2024/031059A2 |
The present disclosure relates to a method of inducing cellular rejuvenation and/or regeneration of a cell or tissue comprising contacting the cell with an effective amount of a protein or nucleic acid encoding a protein that induces cel...
|
|
WO/2024/030845A1 |
Isolated polypeptides that include a cleavable moiety that is a substrate for at least one protease (e.g., MMP) are disclosed. Activatable molecules including the isolated polypeptides are disclosed. Methods of making and using the isola...
|
|
WO/2024/030847A1 |
Isolated polypeptides that include a cleavable moiety that is a substrate for at least one protease (e.g., MMP) are disclosed. Activatable molecules including the isolated polypeptides are disclosed. Methods of making and using the isola...
|
|
WO/2024/026556A1 |
The present disclosure relates to modified coronavirus S protein and virus-like particles (VLPs) comprising modified coronavirus S protein. The present invention also relates to methods of increasing the purity, and/or stability of coron...
|
|
WO/2024/030207A1 |
Dietary supplements, nutraceutical compositions, medical foods, animal feeds, and pharmaceutical compositions for treating osteoarthritis and other osteo-articular conditions involving neuropathy and associated symptoms. A synergistic co...
|
|
WO/2024/028487A1 |
The present invention relates to nerve growth factor (NGF) or a mutein thereof for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said NGF is administered intranasally to said subject.
|
|
WO/2024/027593A1 |
The present invention relates to use of a Jun inhibitor in preparing a medicament for treating heart failure with preserved ejection fraction (HFpEF).
|
|
WO/2024/030617A2 |
This disclosure contemplates methods of improving the growth of damaged cartilage. In certain embodiment, this disclosure relates to methods performing microfracture and applying components reported herein to provide marrow stimulation w...
|
|
WO/2024/030661A1 |
Shape-restoring materials, as well as techniques for generating shape-restoring materials, are described. An example method includes generating a construct by exposing, to UV-visible light, a resin comprising a globular protein, a water-...
|
|
WO/2024/029535A1 |
The present invention provides a polypeptide that specifically recognizes a structurally abnormal protein caused by misfolding, etc. in mammals, and a detection agent and a reduction agent for a structurally abnormal protein with the use...
|
|
WO/2024/029904A1 |
Disclosed herein are an antioxidant composition for cells, comprising hyaluronan and proteoglycan link protein 1 (HAPLN1) or the gene encoding same as an active ingredient, and a method for antioxidation in cells using the composition. A...
|
|
WO/2024/029597A1 |
Provided is a dry eye remedy that can selectively inhibit IFN-γ, has no risk of biological contamination, and can be stored at room temperature. Provided is a dry eye remedy containing, as an active ingredient, a DNA oligonucleotide tha...
|
|
WO/2024/030080A1 |
The present invention generally relates to recombinant polypeptides capable of regulating actin remodelling. In particular, the polypeptides disclosed herein are selective for ADP-actin and may modulate ADP-actin remodelling under energy...
|
|
WO/2024/029593A1 |
The present disclosure includes: a polynucleotide comprising a sequence encoding shortened polycystin-1 (PC1) having a cyst formation-inhibiting activity, in which the shortened PC1 contains a PC1 C-terminal tail (CTT) domain or a part t...
|
|
WO/2024/028417A1 |
The present invention concerns a composition comprising at least one mite peptidase 1 or Matrix metallopeptidase 9 (MMP-9) antagonist, and optionally a pharmaceutically acceptable carrier, for use for preventing and/or treating vitiligo ...
|
|
WO/2024/028912A1 |
The present invention concerns gamma-secretase inhibitors for use in the treatment of inherited epidermolysis bullosa and/or fibrosis associated to inherited epidermolysis bullosa, in particular for use in the treatment of recessive dyst...
|
|
WO/2024/030850A1 |
Isolated polypeptides that include a cleavable moiety that is a substrate for at least one protease (e.g., MT-SP1 and/or an MMP) and isolated polypeptides that include a substrate that has a first cleavable moiety cleavable by a first pr...
|
|
WO/2024/029993A1 |
The present invention relates to a hydrogel patch for wound healing promotion or scar minimization. The use of the hydrogel patch composed of a biocompatible polymer modified with pyrogallol and containing a drug mixture in which PTD-DMB...
|
|
WO/2024/029995A1 |
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, known to be a causative agent of Alzheimer's disease, and a composition for treating and preventing Alzheimer's disease, comprising the...
|
|
WO/2024/029560A1 |
Provided is a therapeutic agent for Hunner-type interstitial cystitis that can selectively inhibit IFN-γ, does not have a risk of biological contamination, and can be stored at room temperature. Provided is a therapeutic agent for Hunne...
|
|
WO/2024/027451A1 |
Provided are an oil-in-water cyclosporin emulsion and a method for preparing same. The oil-in-water cyclosporin emulsion comprises an interface stabilizer comprising a combination of polyethylene glycol (15)-hydroxystearate and phospholi...
|
|
WO/2024/029331A1 |
The present invention provides a pharmaceutical composition that alleviates pain due to joint disease and suppresses cartilage degeneration. One aspect of the present invention relates to a pharmaceutical composition for treating and/o...
|
|
WO/2024/030950A2 |
The disclosure relates to compositions and methods comprising MSH analogs and cell therapy.
|
|
WO/2024/029630A1 |
The present disclosure provides a cyclic peptide derivative, a method for producing the same, and a composition. The present disclosure pertains to a compound for neural cell activity regulation. More specifically, the compound of the pr...
|
|
WO/2024/031036A2 |
The present application provides IL-15 prodrugs comprising the masking polypeptide (MP) and the cleavable moiety (CM). The isolated nucleic acid molecules encoding the IL-15 prodrugs; vectors comprising the nucleic acid molecules; host c...
|
|
WO/2024/029613A1 |
Provided is a compound useful as an active ingredient in a pharmaceutical composition for treating pancreatic cancer. The present inventors carried out investigations with regard to compounds useful as an active ingredient in a pharmac...
|
